Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 310

1.

Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T Cells.

Knight FC, Gilchuk P, Kumar A, Becker KW, Sevimli S, Jacobson ME, Suryadevara N, Wang-Bishop L, Boyd KL, Crowe JE Jr, Joyce S, Wilson JT.

ACS Nano. 2019 Oct 4. doi: 10.1021/acsnano.9b00326. [Epub ahead of print]

PMID:
31553872
2.

Ehrlichia chaffeensis OMP-1-specific human antibody-mediated immunity is defined by intracellular TRIM21-dependent innate immune activation and extracellular neutralization.

Velayutham TS, Kumar S, Zhang X, Kose N, Walker DH, Winslow G, Crowe JE Jr, McBride JW.

Infect Immun. 2019 Sep 23. pii: IAI.00383-19. doi: 10.1128/IAI.00383-19. [Epub ahead of print]

3.

Inappropriate Citation of Vaccine Article.

Reif DM, Chanock SJ, Edwards KM, Crowe JE.

J Infect Dis. 2019 Jun 3. pii: jiz287. doi: 10.1093/infdis/jiz287. [Epub ahead of print] No abstract available.

PMID:
31158294
4.

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.

Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, Elbashir SM, Theisen MA, Humphris-Narayanan E, Ciaramella G, Himansu S, Diamond MS, Crowe JE Jr.

Sci Immunol. 2019 May 17;4(35). pii: eaaw6647. doi: 10.1126/sciimmunol.aaw6647.

PMID:
31101672
5.

A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface.

Bangaru S, Lang S, Schotsaert M, Vanderven HA, Zhu X, Kose N, Bombardi R, Finn JA, Kent SJ, Gilchuk P, Gilchuk I, Turner HL, García-Sastre A, Li S, Ward AB, Wilson IA, Crowe JE Jr.

Cell. 2019 May 16;177(5):1136-1152.e18. doi: 10.1016/j.cell.2019.04.011.

PMID:
31100268
6.

Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.

Colbert MD, Flyak AI, Ogega CO, Kinchen VJ, Massaccesi G, Hernandez M, Davidson E, Doranz BJ, Cox AL, Crowe JE Jr, Bailey JR.

J Virol. 2019 Jun 28;93(14). pii: e02070-18. doi: 10.1128/JVI.02070-18. Print 2019 Jul 15.

PMID:
31068427
7.

Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk.

King LB, West BR, Moyer CL, Gilchuk P, Flyak A, Ilinykh PA, Bombardi R, Hui S, Huang K, Bukreyev A, Crowe JE Jr, Saphire EO.

Nat Commun. 2019 Apr 17;10(1):1788. doi: 10.1038/s41467-019-09732-7.

8.

Structural Diversity of Ultralong CDRH3s in Seven Bovine Antibody Heavy Chains.

Dong J, Finn JA, Larsen PA, Smith TPL, Crowe JE Jr.

Front Immunol. 2019 Mar 22;10:558. doi: 10.3389/fimmu.2019.00558. eCollection 2019.

9.

High frequency of shared clonotypes in human B cell receptor repertoires.

Soto C, Bombardi RG, Branchizio A, Kose N, Matta P, Sevy AM, Sinkovits RS, Gilchuk P, Finn JA, Crowe JE Jr.

Nature. 2019 Feb;566(7744):398-402. doi: 10.1038/s41586-019-0934-8. Epub 2019 Feb 13.

PMID:
30760926
10.

New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications.

Engelhardt BG, Savani U, Jung DK, Powers AC, Jagasia M, Chen H, Winnick JJ, Tamboli RA, Crowe JE Jr, Abumrad NN.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1225-1231. doi: 10.1016/j.bbmt.2019.02.001. Epub 2019 Feb 7.

PMID:
30738170
11.

Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.

Williamson LE, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz BJ, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE Jr.

J Virol. 2019 Apr 3;93(8). pii: e01439-18. doi: 10.1128/JVI.01439-18. Print 2019 Apr 15.

12.

Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice.

Salazar V, Jagger BW, Mongkolsapaya J, Burgomaster KE, Dejnirattisai W, Winkler ES, Fernandez E, Nelson CA, Fremont DH, Pierson TC, Crowe JE Jr, Screaton GR, Diamond MS.

Cell Rep. 2019 Feb 5;26(6):1585-1597.e4. doi: 10.1016/j.celrep.2019.01.052.

13.

Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains.

Turner HL, Pallesen J, Lang S, Bangaru S, Urata S, Li S, Cottrell CA, Bowman CA, Crowe JE Jr, Wilson IA, Ward AB.

PLoS Biol. 2019 Feb 4;17(2):e3000139. doi: 10.1371/journal.pbio.3000139. eCollection 2019 Feb.

14.

Antibody Determinants of Influenza Immunity.

Crowe JE.

J Infect Dis. 2019 Apr 8;219(Supplement_1):S21-S29. doi: 10.1093/infdis/jiz010.

PMID:
30715373
15.

Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope.

Long F, Doyle M, Fernandez E, Miller AS, Klose T, Sevvana M, Bryan A, Davidson E, Doranz BJ, Kuhn RJ, Diamond MS, Crowe JE Jr, Rossmann MG.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1591-1596. doi: 10.1073/pnas.1815432116. Epub 2019 Jan 14.

16.

Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses.

Sevy AM, Wu NC, Gilchuk IM, Parrish EH, Burger S, Yousif D, Nagel MBM, Schey KL, Wilson IA, Crowe JE Jr, Meiler J.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1597-1602. doi: 10.1073/pnas.1806004116. Epub 2019 Jan 14.

17.

Influenza Virus-Specific Human Antibody Repertoire Studies.

Crowe JE Jr.

J Immunol. 2019 Jan 15;202(2):368-373. doi: 10.4049/jimmunol.1801459. Review.

PMID:
30617118
18.

Current Understanding of Humoral Immunity to Enterovirus D68.

Vogt MR, Crowe JE Jr.

J Pediatric Infect Dis Soc. 2018 Dec 26;7(suppl_2):S49-S53. doi: 10.1093/jpids/piy124. Review.

PMID:
30590621
19.

Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.

Chukwuma VU, Kose N, Sather DN, Sapparapu G, Falk R, King H, Singh V, Lampley R, Malherbe DC, Ditto NT, Sullivan JT, Barnes T, Doranz BJ, Labranche CC, Montefiori DC, Kalams SA, Haigwood NL, Crowe JE Jr.

PLoS One. 2018 Dec 19;13(12):e0209437. doi: 10.1371/journal.pone.0209437. eCollection 2018.

20.

Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Kimble JB, Malherbe DC, Meyer M, Gunn BM, Karim MM, Ilinykh PA, Iampietro M, Mohamed KS, Negi S, Gilchuk P, Huang K, Wolf YI, Braun W, Crowe JE, Alter G, Bukreyev A.

J Virol. 2019 Feb 5;93(4). pii: e01845-18. doi: 10.1128/JVI.01845-18. Print 2019 Feb 15.

21.

Human mAbs to Staphylococcus aureus IsdA Provide Protection Through Both Heme-Blocking and Fc-Mediated Mechanisms.

Bennett MR, Bombardi RG, Kose N, Parrish EH, Nagel MB, Petit RA, Read TD, Schey KL, Thomsen IP, Skaar EP, Crowe JE.

J Infect Dis. 2019 Apr 8;219(8):1264-1273. doi: 10.1093/infdis/jiy635.

PMID:
30496483
22.

Mechanism of Enhanced Immature Dengue Virus Attachment to Endosomal Membrane Induced by prM Antibody.

Wirawan M, Fibriansah G, Marzinek JK, Lim XX, Ng TS, Sim AYL, Zhang Q, Kostyuchenko VA, Shi J, Smith SA, Verma CS, Anand G, Crowe JE Jr, Bond PJ, Lok SM.

Structure. 2019 Feb 5;27(2):253-267.e8. doi: 10.1016/j.str.2018.10.009. Epub 2018 Nov 21.

PMID:
30471923
23.

A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.

Goo L, Debbink K, Kose N, Sapparapu G, Doyle MP, Wessel AW, Richner JM, Burgomaster KE, Larman BC, Dowd KA, Diamond MS, Crowe JE Jr, Pierson TC.

Nat Microbiol. 2019 Jan;4(1):71-77. doi: 10.1038/s41564-018-0283-7. Epub 2018 Nov 19.

24.

Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein.

Kim AS, Austin SK, Gardner CL, Zuiani A, Reed DS, Trobaugh DW, Sun C, Basore K, Williamson LE, Crowe JE Jr, Slifka MK, Fremont DH, Klimstra WB, Diamond MS.

Nat Microbiol. 2019 Jan;4(1):187-197. doi: 10.1038/s41564-018-0286-4. Epub 2018 Nov 19.

25.

Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.

Kinchen VJ, Zahid MN, Flyak AI, Soliman MG, Learn GH, Wang S, Davidson E, Doranz BJ, Ray SC, Cox AL, Crowe JE Jr, Bjorkman PJ, Shaw GM, Bailey JR.

Cell Host Microbe. 2018 Nov 14;24(5):717-730.e5. doi: 10.1016/j.chom.2018.10.012.

PMID:
30439341
26.

HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.

Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE Jr, Bailey JR, Bjorkman PJ.

Cell Host Microbe. 2018 Nov 14;24(5):703-716.e3. doi: 10.1016/j.chom.2018.10.009.

PMID:
30439340
27.

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model.

Patel A, Park DH, Davis CW, Smith TRF, Leung A, Tierney K, Bryan A, Davidson E, Yu X, Racine T, Reed C, Gorman ME, Wise MC, Elliott STC, Esquivel R, Yan J, Chen J, Muthumani K, Doranz BJ, Saphire EO, Crowe JE, Broderick KE, Kobinger GP, He S, Qiu X, Kobasa D, Humeau L, Sardesai NY, Ahmed R, Weiner DB.

Cell Rep. 2018 Nov 13;25(7):1982-1993.e4. doi: 10.1016/j.celrep.2018.10.062.

28.

Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.

Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, Screaton G, Crowe JE Jr, Wang WK.

J Virol. 2018 Nov 12;92(23). pii: e00556-18. doi: 10.1128/JVI.00556-18. Print 2018 Dec 1.

29.

Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses.

Alvarado G, Ettayebi K, Atmar RL, Bombardi RG, Kose N, Estes MK, Crowe JE Jr.

Gastroenterology. 2018 Dec;155(6):1898-1907. doi: 10.1053/j.gastro.2018.08.039. Epub 2018 Aug 28.

PMID:
30170116
30.

Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap.

Ilinykh PA, Santos RI, Gunn BM, Kuzmina NA, Shen X, Huang K, Gilchuk P, Flyak AI, Younan P, Alter G, Crowe JE Jr, Bukreyev A.

PLoS Pathog. 2018 Aug 23;14(8):e1007204. doi: 10.1371/journal.ppat.1007204. eCollection 2018 Aug.

31.

Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors.

Meyer M, Yoshida A, Ramanathan P, Saphire EO, Collins PL, Crowe JE Jr, Samal S, Bukreyev A.

Cell Rep. 2018 Aug 14;24(7):1816-1829. doi: 10.1016/j.celrep.2018.07.044.

32.

Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.

Kuzmina NA, Younan P, Gilchuk P, Santos RI, Flyak AI, Ilinykh PA, Huang K, Lubaki NM, Ramanathan P, Crowe JE Jr, Bukreyev A.

Cell Rep. 2018 Aug 14;24(7):1802-1815.e5. doi: 10.1016/j.celrep.2018.07.035.

33.

Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.

Bramble MS, Hoff N, Gilchuk P, Mukadi P, Lu K, Doshi RH, Steffen I, Nicholson BP, Lipson A, Vashist N, Sinai C, Spencer D, Olinger G, Wemakoy EO, Illunga BK, Pettitt J, Logue J, Marchand J, Varughese J, Bennett RS, Jahrling P, Cavet G, Serafini T, Ollmann Saphire E, Vilain E, Muyembe-Tamfum JJ, Hensely LE, Simmons G, Crowe JE Jr, Rimoin AW.

J Infect Dis. 2018 Nov 5;218(12):1929-1936. doi: 10.1093/infdis/jiy453.

34.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

35.

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus.

Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K, Krause T, Qiu X, He S, Das J, Suscovich TJ, Lai J, Chandran K, Zeitlin L, Crowe JE Jr, Lauffenburger D, Kawaoka Y, Kobinger GP, Andersen KG, Dye JM, Saphire EO, Alter G.

Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5. doi: 10.1016/j.chom.2018.07.009.

36.

Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies.

Ilinykh PA, Graber J, Kuzmina NA, Huang K, Ksiazek TG, Crowe JE Jr, Bukreyev A.

J Infect Dis. 2018 Nov 22;218(suppl_5):S418-S422. doi: 10.1093/infdis/jiy423.

PMID:
30060231
37.

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.

Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, Turner HL, Fusco ML, Bramble MS, Hoff NA, Binshtein E, Kose N, Flyak AI, Flinko R, Orlandi C, Carnahan R, Parrish EH, Sevy AM, Bombardi RG, Singh PK, Mukadi P, Muyembe-Tamfum JJ, Ohi MD, Saphire EO, Lewis GK, Alter G, Ward AB, Rimoin AW, Bukreyev A, Crowe JE Jr.

Immunity. 2018 Aug 21;49(2):363-374.e10. doi: 10.1016/j.immuni.2018.06.018. Epub 2018 Jul 17.

38.

A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA.

Bangaru S, Zhang H, Gilchuk IM, Voss TG, Irving RP, Gilchuk P, Matta P, Zhu X, Lang S, Nieusma T, Richt JA, Albrecht RA, Vanderven HA, Bombardi R, Kent SJ, Ward AB, Wilson IA, Crowe JE Jr.

Nat Commun. 2018 Jul 10;9(1):2669. doi: 10.1038/s41467-018-04704-9.

39.

Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates.

Gilchuk P, Mire CE, Geisbert JB, Agans KN, Deer DJ, Cross RW, Slaughter JC, Flyak AI, Mani J, Pauly MH, Velasco J, Whaley KJ, Zeitlin L, Geisbert TW, Crowe JE Jr.

J Infect Dis. 2018 Nov 22;218(suppl_5):S565-S573. doi: 10.1093/infdis/jiy295.

PMID:
29982718
40.

Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection.

Setliff I, McDonnell WJ, Raju N, Bombardi RG, Murji AA, Scheepers C, Ziki R, Mynhardt C, Shepherd BE, Mamchak AA, Garrett N, Karim SA, Mallal SA, Crowe JE Jr, Morris L, Georgiev IS.

Cell Host Microbe. 2018 Jun 13;23(6):845-854.e6. doi: 10.1016/j.chom.2018.05.001. Epub 2018 May 31.

41.

Mxra8 is a receptor for multiple arthritogenic alphaviruses.

Zhang R, Kim AS, Fox JM, Nair S, Basore K, Klimstra WB, Rimkunas R, Fong RH, Lin H, Poddar S, Crowe JE Jr, Doranz BJ, Fremont DH, Diamond MS.

Nature. 2018 May;557(7706):570-574. doi: 10.1038/s41586-018-0121-3. Epub 2018 May 16.

42.

Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.

Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, Gulka CP, Ilinykh PA, Shen X, Huang K, Ramanathan P, Turner H, Fusco ML, Lampley R, Kose N, King H, Sapparapu G, Doranz BJ, Ksiazek TG, Wright DW, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr.

Nat Microbiol. 2018 Jun;3(6):670-677. doi: 10.1038/s41564-018-0157-z. Epub 2018 May 7.

43.

Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes.

Lecouturier V, Berry C, Saulnier A, Naville S, Manin C, Girerd-Chambaz Y, Crowe JE Jr, Jackson N, Guy B.

Vaccine. 2019 Jul 26;37(32):4601-4609. doi: 10.1016/j.vaccine.2018.04.065. Epub 2018 Apr 26.

44.

Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus.

Fernandez E, Kose N, Edeling MA, Adhikari J, Sapparapu G, Lazarte SM, Nelson CA, Govero J, Gross ML, Fremont DH, Crowe JE Jr, Diamond MS.

MBio. 2018 Feb 27;9(1). pii: e00008-18. doi: 10.1128/mBio.00008-18.

45.

Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins.

Mousa JJ, Binshtein E, Human S, Fong RH, Alvarado G, Doranz BJ, Moore ML, Ohi MD, Crowe JE Jr.

PLoS Pathog. 2018 Feb 22;14(2):e1006837. doi: 10.1371/journal.ppat.1006837. eCollection 2018 Feb.

46.

Integrating linear optimization with structural modeling to increase HIV neutralization breadth.

Sevy AM, Panda S, Crowe JE Jr, Meiler J, Vorobeychik Y.

PLoS Comput Biol. 2018 Feb 16;14(2):e1005999. doi: 10.1371/journal.pcbi.1005999. eCollection 2018 Feb.

47.

The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding.

King LB, Fusco ML, Flyak AI, Ilinykh PA, Huang K, Gunn B, Kirchdoerfer RN, Hastie KM, Sangha AK, Meiler J, Alter G, Bukreyev A, Crowe JE Jr, Saphire EO.

Cell Host Microbe. 2018 Jan 10;23(1):101-109.e4. doi: 10.1016/j.chom.2017.12.003.

48.

Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.

Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE Jr, Bailey JR.

Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):E82-E91. doi: 10.1073/pnas.1718441115. Epub 2017 Dec 18.

49.

Role of Non-local Interactions between CDR Loops in Binding Affinity of MR78 Antibody to Marburg Virus Glycoprotein.

Sangha AK, Dong J, Williamson L, Hashiguchi T, Saphire EO, Crowe JE Jr, Meiler J.

Structure. 2017 Dec 5;25(12):1820-1828.e2. doi: 10.1016/j.str.2017.10.005. Epub 2017 Nov 16.

50.

Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8.

Matho MH, Schlossman A, Gilchuk IM, Miller G, Mikulski Z, Hupfer M, Wang J, Bitra A, Meng X, Xiang Y, Kaever T, Doukov T, Ley K, Crotty S, Peters B, Hsieh-Wilson LC, Crowe JE Jr, Zajonc DM.

J Biol Chem. 2018 Jan 5;293(1):390-401. doi: 10.1074/jbc.M117.814541. Epub 2017 Nov 9.

Supplemental Content

Loading ...
Support Center